(in Harousseau et al). Novel biologically-based therapies targeting multiple myeloma (MM) cells and the bone marrow (BM) microenvironment: A. induce G1 growth arrest and apoptosis in MM cell lines and patient cells resistant to conventional chemotherapy; B. decrease MM cell-BM stromal cell binding; C. decrease cytokine production and sequelae in the BM microenvironment; D. decrease angiogenesis; and E. induce host anti-MM immunity.